Cumulative incidences of severe GVHD and NRM. (A-B) Comparison of the 20-mg and > 20-mg cohorts for cumulative incidences of severe GVHD (acute pattern grade III-IV GVHD or severe extensive GVHD; A) and NRM (B) as evaluated by competing risk (P < .001 for GVHD comparison). (C-D) Comparison of the 30-mg and > 30-mg cohorts for cumulative incidences of severe GVHD (C) and NRM (D).